Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.
Feng S, Gane E, Schwabe C, Zhu M, Triyatni M, Zhou J, Bo Q, Jin Y. Feng S, et al. Among authors: jin y. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01323-20. doi: 10.1128/AAC.01323-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32839221 Free PMC article. Clinical Trial.
How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug.
Cosson V, Feng S, Jaminion F, Lemenuel-Diot A, Parrott N, Paehler A, Bo Q, Jin Y. Cosson V, et al. Among authors: jin y. Clin Pharmacol Ther. 2021 Apr;109(4):1081-1091. doi: 10.1002/cpt.2184. Epub 2021 Mar 10. Clin Pharmacol Ther. 2021. PMID: 33523474 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
Yuen MF, Zhou X, Gane E, Schwabe C, Tanwandee T, Feng S, Jin Y, Triyatni M, Lemenuel-Diot A, Cosson V, Xue Z, Kazma R, Bo Q. Yuen MF, et al. Among authors: jin y. Lancet Gastroenterol Hepatol. 2021 Sep;6(9):723-732. doi: 10.1016/S2468-1253(21)00176-X. Epub 2021 Jul 6. Lancet Gastroenterol Hepatol. 2021. PMID: 34237271 Clinical Trial.
Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor.
Kratochwil NA, Triyatni M, Mueller MB, Klammers F, Leonard B, Turley D, Schmaler J, Ekiciler A, Molitor B, Walter I, Gonsard PA, Tournillac CA, Durrwell A, Marschmann M, Jones R, Ullah M, Boess F, Ottaviani G, Jin Y, Parrott NJ, Fowler S. Kratochwil NA, et al. Among authors: jin y. J Pharmacol Exp Ther. 2018 May;365(2):237-248. doi: 10.1124/jpet.117.245712. Epub 2018 Feb 16. J Pharmacol Exp Ther. 2018. PMID: 29453199
What drives the dynamics of HBV RNA during treatment?
Gonçalves A, Lemenuel-Diot A, Cosson V, Jin Y, Feng S, Bo Q, Guedj J. Gonçalves A, et al. Among authors: jin y. J Viral Hepat. 2021 Feb;28(2):383-392. doi: 10.1111/jvh.13425. Epub 2020 Nov 2. J Viral Hepat. 2021. PMID: 33074571
Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Müller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR. Jin Y, et al. J Clin Pharmacol. 2010 Jan;50(1):62-72. doi: 10.1177/0091270009337946. Epub 2009 Oct 19. J Clin Pharmacol. 2010. PMID: 19841156 Free PMC article. Clinical Trial.
21,596 results
You have reached the last available page of results. Please see the User Guide for more information.